LY 355703

Drug Profile

LY 355703

Alternative Names: C-52; cryptophycin 52; Multi-drug resistance inhibitor cryptophycin 52

Latest Information Update: 27 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Depsipeptides; Lactams; Lactones
  • Mechanism of Action Microtubule protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 25 Mar 2003 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 12 Aug 2002 A phase II study in non-small cell lung cancer has been added to the Cancer therapeutic trials and adverse events sections
  • 02 Nov 2001 Phase-II clinical trials in Non-small cell lung cancer in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top